Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Emyria Ltd ( (AU:EMD) ) has provided an update.
Emyria Limited has announced a landmark reimbursement agreement with Medibank, Australia’s largest private health insurer, which will provide coverage for eligible members with PTSD to access Emyria’s psychiatrist-led program at Perth Clinic. This development, highlighted at the Psychedelic Science 2025 conference, positions Emyria as a global leader in creating sustainable funding pathways for complex mental health care models, addressing significant barriers in scaling psychotherapy models.
More about Emyria Ltd
Emyria Limited is a company focused on developing and delivering innovative mental health treatments and select neurological conditions through an integrated model of direct clinical services and treatment development. The company offers evidence-based treatments for patients who do not find relief from conventional care and evaluates emerging therapies like assisted therapy for PTSD and treatment-resistant depression. Emyria also gathers robust, ethically sourced real-world data to improve its therapy and drug development programs, with a pipeline that includes new psychedelic-assisted therapies and drug treatments.
Average Trading Volume: 672,353
Technical Sentiment Signal: Sell
Current Market Cap: A$12.28M
For detailed information about EMD stock, go to TipRanks’ Stock Analysis page.